Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

A9583 Gadofosveset trisodium injection

A Codes

Also known as: Ablavar, gadofosveset

Gadofosveset trisodium injection used as a gadolinium-based vascular magnetic resonance imaging contrast agent.

In Plain Language

blood vessel MRI dye; vascular contrast agent

Clinical Context

Used in magnetic resonance angiography for imaging blood vessels with prolonged intravascular imaging time.

RVU Information

CPT A9583 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

HCPCS A-codes cover medical supplies, equipment, and transport services. Documentation must establish medical necessity and include a physician order. For durable medical equipment (DME), a Certificate of Medical Necessity (CMN) or detailed written order may be required.

Specialties

RadiologyVascular SurgeryCardiology

Frequently Asked Questions

What is CPT code A9583?

CPT A9583 (Gadofosveset trisodium injection) is a A Codes code. Gadofosveset trisodium injection used as a gadolinium-based vascular magnetic resonance imaging contrast agent.

Does Medicare cover A9583?

Medicare coverage for A9583 depends on medical necessity and applicable Local Coverage Determinations (LCDs). Used in magnetic resonance angiography for imaging blood vessels with prolonged intravascular imaging time. A physician order is typically required.

When is CPT A9583 used?

Used in magnetic resonance angiography for imaging blood vessels with prolonged intravascular imaging time.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against national data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.